$27.00
+0.59(2.25%)
Mkt Cap $1.8B
$11.77
$47.33
52-Week Range
At a Glance
AI-generatedMineralys Therapeutics, Inc.
8-K
Mineralys Therapeutics, Inc. announced fourth quarter and full year 2025 financial results, reporting net loss of $32.2 million for Q4 and $154.7 million for the year, with cash position of $656.6 million as of December 31, 2025. The FDA accepted the NDA for lorundrostat for hypertension treatment, assigning a PDUFA target date of December 22, 2026.$1.8B
Market Cap
—
Revenue
-$127M
Net Income
Employees51
Fundamentals
How The Business Makes Money
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001933414
ISINUS6031701013
CUSIP603170101
Phone888-378-6240
Address150 N. Radnor Chester Rd., Radnor, PA, 19087, US
SEC EDGAR